<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04781426</url>
  </required_header>
  <id_info>
    <org_study_id>OXTREC 49-20</org_study_id>
    <nct_id>NCT04781426</nct_id>
  </id_info>
  <brief_title>PrEP Among MSM and TG in Myanmar</brief_title>
  <acronym>PrEP</acronym>
  <official_title>Pre-exposure Prophylaxis of HIV Infection Among Men Who Have Sex With Men (MSM) and Transgender Women (TG) in Suburban Yangon, Myanmar</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Myanmar Oxford Clinical Research Unit</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Action Myanmar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Myanmar Oxford Clinical Research Unit</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV is concentrated among key populations in Myanmar. Globally, HIV-prevalence among&#xD;
      transgender (TG) women is one of the highest; laboratory-confirmed prevalence is reported up&#xD;
      to 40%. In September 2015, WHO recommended the use of Pre-Exposure Prophylaxis (PrEP) for&#xD;
      people at substantial risk of HIV as part of a combination HIV prevention strategy. A&#xD;
      demonstration project will take place to implement and evaluate the uptake and effectiveness&#xD;
      of PrEP among MSM, and TG women in a clinic in Hlaingtharyar township, Yangon. The aim is to&#xD;
      describe PrEP uptake, as well as HIV-seroconversion and STI infection rates among those who&#xD;
      use PrEP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Uptake rate of PrEP</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The proportion of HIV-negative MSM and TG women who are taking PrEP among those who are eligible to take PrEP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV seroconversion rate among PrEP user</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The portion of PrEP taking HIV negative MSM and TG women who become HIV positive while he is taking PrEP among those who are taking PrEP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STI infection rates among PrEP user(Syphilis test, Gram stain for gonorrhoea and Xpert CT/NG)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The number of positive episodes for either syphilis or gonorrhea or chlamydia infection among the PrEP taking MSM and Transgender women per number of testing among them.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>HIV-negative MSM/TG</arm_group_label>
    <description>Oral pre-exposure prophylaxis (PrEP) will be offered to HIV negative MSM, TG identified to be at substantial risk for HIV infection and those motivated to take daily PrEP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate (TDF) 300 mg</intervention_name>
    <description>PrEP regimens of Tenofovir Disoproxil Fumarate (TDF) 300 mg/Lamivudine (3TC) 300mg per oral (PO) daily</description>
    <arm_group_label>HIV-negative MSM/TG</arm_group_label>
    <other_name>Lamivudine (3TC) 300mg</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals self-identified as belonging to the MSM and/or TG population who are eligible&#xD;
        in line with selection criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-negative&#xD;
&#xD;
          -  No suspicion of acute HIV infection&#xD;
&#xD;
          -  Substantial risk of HIV infection&#xD;
&#xD;
          -  Creatinine clearance is more than 30 ml/min&#xD;
&#xD;
          -  Willingness to use PrEP as prescribed, including periodic HIV testing&#xD;
&#xD;
          -  Willingness to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ Anyone who is not eligible with the inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NiNi Tun, MB BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Action Myanmar</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ni Ni Tun, MB BS</last_name>
    <phone>+951544537</phone>
    <email>nini@medicalactionmyanmar.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Htet Htet Aung, BA</last_name>
    <phone>+951544537</phone>
    <email>HtetHtetAung@tropmedres.ac</email>
  </overall_contact_backup>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre-exposure prophylaxis of HIV infection</keyword>
  <keyword>PrEP</keyword>
  <keyword>MSM</keyword>
  <keyword>TG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

